Pharmaceutical Technology Europe-09-02-2012

i3_t-786301-1408595149536.jpg

Pharmaceutical Technology Europe

Spray drying is a key process for manufacturing amorphous dispersions because of its breadth of applicability. The wide range of potential atomization techniques and controllable drying kinetics enables amorphous spray-dried dispersions (SDDs) to be produced from a wide variety of active pharmaceutical ingredients (APIs).

i4-786302-1408595144800.jpg

Pharmaceutical Technology Europe

Solubilizers play an important role in dissolving poorly soluble molecules. As the number of poorly soluble lipophilic and/or hydrophobic molecules increases-whether as "brick dusts" or waxy substances-the industry is struggling to identify the appropriate lipophilic excipients (surfactants, solubilizers, solvents or polymers) that can be used to develop such poorly soluble formulations into solid dosages and other forms of pharmaceutical products.

i1-786303-1408595137479.jpg

Pharmaceutical Technology Europe

In drug development, the majority of new chemical entities are lipophilic and/or poorly soluble. New actives often fail during development due to these challenging properties.

i1-786304-1408599715974.jpg

Open Alliance

Pharmaceutical Technology Europe

A round table with Catalent and BASF on their new collaboration to provide bioavailability solutions.

Pharmaceutical Technology Europe

Development of viable dosage forms for poorly water-soluble compounds continues to be a significant challenge for formulation scientists, and insufficient bioavailability of such compounds may result in development delays or failures.